ProCE Banner Series

Unfolding Immunotherapy in Head and Neck Cancers

Register for this webinar where expert faculty describe the rationale and latest strategies for incorporating immune checkpoint inhibitors into the clinical management of patients with recurrent or metastatic head and neck squamous cell carcinomas.

  AMA
Who Should Attend

This educational program is intended for medical, surgical, and radiation oncologists and other healthcare professionals who treat patients with head and neck cancer.

All Events

Unfolding Immunotherapy in Head and Neck Cancers

Past Events

August

24

2023

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Topics

  • Rationale for targeting the immune system in head and neck squamous cell carcinoma
  • First-line treatment of metastatic, or unresectable, recurrent HNSCC with immune checkpoint inhibitors
  • Integrating immune checkpoint inhibitors into the second-line management of recurrent or metastatic HNSCC
  • Managing treatment-related adverse events associated with immune checkpoint inhibitors
  • Looking Forward

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners to apply immunotherapy in the treatment of patients with head and neck cancer.

Target Audience
This educational program is intended for medical, surgical, and radiation oncologists and other healthcare professionals who treat patients with head and neck cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Analyze the role of the immune system and immune escape in HNSCC, and distinguish the mechanisms of action of different immunomodulatory agents
  • Synthesize the application of immune checkpoint inhibitors in the clinical management of patients with recurrent or metastatic HNSCC in both the frontline and relapsed/refractory settings through the integration of evidence-based practice
  • Evaluate, classify, and manage the unique spectrum of adverse events related to immune checkpoint inhibitors using critical-thinking skills and knowledge of best practices
  • Evaluate the latest scientific and clinical trial outcomes concerning immune checkpoint inhibitors alone or in combination with radiotherapy or biotherapy in adjuvant and neoadjuvant settings using an evidence-based approach

 

 

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from Merck Sharp & Dohme LLC.